Alzheimer’s Disease Market overview

Innovative treatments for Alzheimer's Disease, including AR1001, AGB101, AMX0035, IVL3003, BHV-8000, and more, are poised to drive growth in the Alzheimer's Disease Market in the near future.

DelveInsight has released a comprehensive report titled "Alzheimer's Disease - Market Insights, Epidemiology, and Market Forecast-2034," offering detailed insights into Alzheimer's Disease, its historical and projected epidemiology, and market trends in Japan.

Discover about the Alzheimer's Disease market report @ https://www.delveinsight.com/report-store/alzheimers-disease-japan-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key highlights from the Alzheimer's Disease Market Report include:

• In 2024, Germany had the highest diagnosed prevalent Alzheimer's cases in EU4 and UK (30%), followed by France (24%), with rising projections.
• US: 2.4 million men and 5 million women affected in 2024, expected to grow by 2034.
• EU4/UK: 75-84 age group had ~2 million cases in 2024; under 65: ~130,000.
• Japan: 2.5 million diagnosed agitation cases in 2024, projected to increase by 2034, impacting quality of life and caregivers.
• US: 44% of 7MM cases (7 million in 2024), rising by 2034, straining healthcare.
• June 2025: Hoffmann-La Roche studying RO7126209 in prodromal/mild AD.
• June 2025: Annovis Bio testing buntanetap in early-stage AD (ages 55-85).
• June 2025: Eli Lilly evaluating therapy to delay Alzheimer's progression.
• UCB Biopharma assessing bepranemab on CDR-SB in prodromal/mild AD.
• Key companies like Anavex, TauRx, BioVie, AriBio, Novo Nordisk, AgeneBio, Neurim, Eisai, T3D, Merck Sharp & Dohme, Shanghai Hengrui, NeuroSense, Pharmazz, Johnson & Johnson, NKGen, LEXEO, Inventage, Neumora, Takeda, Perha, Luye, Eli Lilly, Prothena, Therabest, Neurotez, TRIMTECH, Lexeo, and others are advancing therapies. Eisai leads Asian efforts with lecanemab (Phase 3, marketed, ~27% decline slowdown on CDR-SB, FDA/Japan approved, ongoing extensions/subcutaneous/prevention trials) and E2814 (Phase 2/3, anti-tau). Takeda: TAK-071 (Phase 2, M1 modulator) and TAK-341 (early M4 work). Otsuka: AVP-786 (Phase 3, agitation). Sumitomo: SEP-363856 (Phase 2, psychosis). Shionogi: S-217622 (Phase 1, neuroinflammation). Daiichi Sankyo: DS-1248 (Phase 2, sleep modulation). South Korea: Samsung Bioepis (SB-11 biosimilars, Phase 1/3); AriBio (AR1001, Phase 3, PDE-5 inhibitor, FDA Fast Track); Mediforum (PM012, Phase 2, herbal); GemVax (GV1001, Phase 2/3, telomerase peptide); NeuroBo (NB-01, Phase 2, insulin sensitizer); Cellivery (CP-AD, Phase 1, protein delivery). Taiwan: TWi (AC-1101, Phase 2, neuroprotective); Lumosa (LT3001, Phase 2, neurovascular); APRINOIA (APN-1607, Phase 2/3, tau inhibitor); SyneuRx (NA-831, Phase 2, BDNF enhancer).
• Promising therapies: AR1001, AGB101, AMX0035, IVL3003, BHV-8000, and others.

Alzheimer's Disease Overview

Alzheimer's disease is a progressive neurological disorder impairing memory, cognition, and reasoning, causing 60-80% of dementia. It typically starts in mid-60s, linked to amyloid plaques and tau tangles. Risk factors: age and genetics.

Discover how the Alzheimer's Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/alzheimers-disease-japan-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Alzheimer's Disease Emerging Drugs

• AR1001: AriBio Co., Ltd.
• AGB101: AgeneBio
• AMX0035: Amylyx Pharmaceuticals Inc
• IVL3003: Inventage Lab., Inc.
• BHV-8000: Biohaven Pharmaceuticals

Scope of the Alzheimer's Disease Market Report

• Study Period: 2020-2034
• Coverage: Japan
• Key Companies: Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuticals, Eisai Inc., T3D Therapeutics, Merck Sharp & Dohme, Shanghai Hengrui Pharmaceutical, NeuroSense Therapeutics, Pharmazz, Johnson & Johnson Innovative Medicine, NKGen Biotech, LEXEO Therapeutics, Inventage Lab, Neumora Therapeutics, Takeda, Perha Pharmaceuticals, Luye Pharma Group Ltd., Eli Lilly and Company, Prothena, Therabest Korea, Neurotez, TRIMTECH Therapeutics, Lexeo Therapeutics, and others
• Therapies: AR1001, AGB101, AMX0035, IVL3003, BHV-8000, and others.
• Therapeutic Assessment: Current marketed and emerging therapies
• Market Dynamics: Drivers and barriers
• Competitive Intelligence: SWOT, PESTLE, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL/Analyst views, Market Access and Reimbursement

To know what's more in our Alzheimer's Disease report, visit https://www.delveinsight.com/report-store/alzheimers-disease-japan-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key benefits of the Alzheimer's Disease Market Report:

• Detailed overview and analysis of epidemiology and market in 7MM (US, EU5, Japan).
• Insights into current and emerging therapies.
• Historical and forecasted market data, including drug outreach.
• Competitive edge for business strategies via trend identification.

Got queries? Click here to know more about the Alzheimer's Disease market Landscape https://www.delveinsight.com/sample-request/alzheimers-disease-japan-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Important Strategic Takeaways: Asian pipeline is diversified with amyloid removal (Eisai, Samsung), tau targeting (Eisai, APRINOIA), neuroinflammation (Shionogi, GemVax), synaptic plasticity (AriBio, SyneuRx), cholinergic (Takeda), neuropsychiatric (Otsuka, Sumitomo), neurovascular/metabolic (TWi, Lumosa, NeuroBo). Regional focus: Japan (antibodies/neuropsychiatry), Korea (repurposed/mitochondrial), Taiwan (neuroprotection/theranostics). Advanced therapies: Lecanemab (marketed), AR1001 (Phase 3), E2814 (Phase 2/3), GV1001 (Phase 2/3), APN-1607 (Phase 2/3).

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Related report

Alzheimer's disease (AD) - Epidemiology Forecast - 2034

DelveInsight’s “Alzheimer’s Disease – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Alzheimer’s Disease, historical and forecasted epidemiology of Alzheimer’s Disease in the United States, EU4 (Germany, France, Italy, and Spain) and the , United Kingdom, and Japan. The leading companies Biogen/Eisai, BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, and others.

Alzheimer's disease (AD) - Pipeline Insight, 2025

DelveInsight’s, “Alzheimer’s disease Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Alzheimer’s disease pipeline landscape. The leading companies Biogen/Eisai, BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, and others.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com